BackOrchestra BioMed Holdings Overview

Orchestra BioMed Holdings Other Liabilities

Track Orchestra BioMed Holdings's other liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00

Peer average

Loading

Orchestra BioMed Holdings Other Liabilities History

Loading

Orchestra BioMed Holdings vs. peers: Other Liabilities Comparison

Loading

Orchestra BioMed Holdings Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Orchestra BioMed Holdings (OBIO) FAQ

The latest other liabilities for OBIO is $0 as of March 2026. In the prior-year period, the figure was $0. Investors often review this figure alongside Orchestra BioMed Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, OBIO's other liabilities moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Orchestra BioMed Holdings's operating scale or balance-sheet position.

A other liabilities figure of $0 for OBIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting OBIO's other liabilities ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.